Pasar al contenido principal

IMPACTO DE LAS PRACTICAS DE CULTIVO EN PLANTAS DE ARROZ QUE ACUMULAN UNA COMBINACION DE MICROBICIDAS EN EL ENDOSPERMO DE SUS SEMILLAS

AGL2017-85377-R

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2017
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE LLEIDA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 14
Encontrada(s) 1 página(s)

Repositori Obert UdL
Publicación Artículo científico (JournalArticle)

Inactivation of rice starch branching enzyme IIb triggers broad and unexpected changes in metabolism by transcriptional reprogramming

  • Baysal, Can
  • He, Wenshu
  • Drapal, Margit
  • Villorbina Noguera, Gemma
  • Medina Piles, Vicente
  • Capell Capell, Teresa
  • Khush, Gurdev S.
  • Zhu, Changfu
  • Fraser, Paul
  • Christou, Paul
Starch properties can be modified by mutating genes responsible for the synthesis of amylose and amylopectin in the endosperm. However, little is known about the effects of such targeted modifications on the overall starch biosynthesis pathway and broader metabolism. Here we investigated the effects of mutating the OsSBEIIb gene encoding starch branching enzyme IIb, which is required for amylopectin synthesis in the endosperm. As anticipated, homozygous mutant plants, in which OsSBEIIb was completely inactivated by abolishing the catalytic center and C-terminal regulatory domain, produced opaque seeds with depleted starch reserves. Amylose content in the mutant increased from 19.6 to 27.4% and resistant starch (RS) content increased from 0.2 to 17.2%. Many genes encoding isoforms of AGPase, soluble starch synthase, and other starch branching enzymes were up-regulated, either in their native tissues or in an ectopic manner, whereas genes encoding granule-bound starch synthase, debranching enzymes, pullulanase, and starch phosphorylases were largely down-regulated. There was a general increase in the accumulation of sugars, fatty acids, amino acids, and phytosterols in the mutant endosperm, suggesting that intermediates in the starch biosynthesis pathway increased flux through spillover pathways causing a profound impact on the accumulation of multiple primary and secondary metabolites. Our results provide insights into the broader implications of perturbing starch metabolism in rice endosperm and its impact on the whole plant, which will make it easier to predict the effect of metabolic engineering in cereals for nutritional improvement or the production of valuable metabolites., We would like to acknowledge funding from Ministry of Economy and Competitiveness, Spain (RTI2018-097613-BI00 to C.Z., PGC2018-097655-B-I00 to P.C., and AGL2017-85377-R to T.C.); Generalitat de Catalunya Grant 2017 SGR 828 to the Agricultural Biotechnology and Bioeconomy Unit; and the European Union Framework Program DISCO (from discovery to final products: a next-generation pipeline for the sustainable generation of high-value plant products; Project 613513) to P.D.F.
Repositori Obert UdL
Publicación Artículo científico (JournalArticle)

Contributions of the international plant science community to the fight against infectious diseases in humans - part 2: endemic and re-emerging diseases

  • He, Wenshu
  • Baysal, Can
  • Lobato, Maria
  • Huang, Xin
  • Alvarez, Derry
  • Zhu, Changfu
  • Armario-Nájera, Victoria
  • Blanco Perera, Amaya
  • Cerda, Pedro
  • Saba-Mayoral, Andrea
  • Sobrino-Mengual, Guillermo
  • Vargheese, Ashwin
  • Abranches, Rita
  • Abreu, Isabel Alexandra
  • Balamurugan, Shanmugaraj
  • Bock, Ralph
  • Buyel, Johannes F.
  • Cunha, Nicolau B. da
  • Daniell, Henry
  • Faller, Roland
  • Folgado, André
  • Gowtham, Iyappan
  • Häkkinen, Suvi
  • Kumar, Shashi
  • Sathish Kumar, Ramalingam
  • Lacorte, Cristiano
  • Lomonossoff, George P.
  • Luís, Ines M.
  • Ma, Julian K-C
  • McDonald, Karen A.
  • Murad, Andre
  • Nandi, Somen
  • O'Keef, Barry
  • Parthiban, Subramanian
  • Paul, Mathew J.
  • Ponndorf, Daniel
  • Rech, Elibio
  • Rodrigues, Julio C. M.
  • Ruf, Stephanie
  • Schillberg, Stefan
  • Schwestka, Jennifer
  • Shah, Priya S.
  • Singh, Rahul
  • Stoger, Eva
  • Twyman, Richard M.
  • Varghese, Inchakalody P.
  • Vianna, Giovanni R.
  • Webster, Gina
  • Wilbers, Ruud H. P.
  • Christou, Paul
  • Oksman-Caldentey, Kirsi-Marja
  • Capell Capell, Teresa
The fight against infectious diseases often focuses on epidemics and pandemics, which demand urgent resources and command attention from the health authorities and media. However, the vast majority of deaths caused by infectious diseases occur in endemic zones, particularly in developing countries, placing a disproportionate burden on underfunded health systems and often requiring international interventions. The provision of vaccines and other biologics is hampered not only by the high cost and limited scalability of traditional manufacturing platforms based on microbial and animal cells, but also by challenges caused by distribution and storage, particularly in regions without a complete cold chain. In this review article, we consider the potential of molecular farming to address the challenges of endemic and re-emerging diseases, focusing on edible plants for the development of oral drugs. Key recent developments in this field include successful clinical trials based on orally delivered dried leaves of Artemisia annua against malarial parasite strains resistant to artemisinin combination therapy, the ability to produce clinical-grade protein drugs in leaves to treat infectious diseases and the long-term storage of protein drugs in dried leaves at ambient temperatures. Recent FDA approval of the first orally delivered protein drug encapsulated in plant cells to treat peanut allergy has opened the door for the development of affordable oral drugs that can be manufactured and distributed in remote areas without cold storage infrastructure and that eliminate the need for expensive purification steps and sterile delivery by injection., The authors would like to thank the Spanish Ministry of Economy, Industry and Competitiveness (project AGL2017-85377-R), the Spanish Ministry of Science, Innovation and Universities (projects RTI2018-097613-B-I00 and PGC2018-097655-B-I00), the EU Horizon 2020 project Pharma-Factory (774078) and the Gener- alitat de Catalunya (Grups Consolidats2017-SGR828); Ag encia de Gesti o d’Ajuts Universitaris i de Recerca (AGAUR), Departament d’Empresa i Coneixement de la Generalitat de Catalunya (PAND EMIES 2020); Project LISBOA-01-0145-FEDER-007660 (Microbiologia Molecular, Estrutural e Celular funded by FEDER funds through COMPETE2020)—Programa Operacional Compet- itividade e Internacionalizacß~ao (POCI) and by the FCT (Portugal) through the R&D Unit, UIDB/04551/2020 (GREEN-IT—Biore- sources for Sustainability); UKIERI and the Hotung Foundation for sustained support of the Bharathiar University / St. George’s Univ. of London collaboration and the Molecular Immunology Unit at St. George’s Univ. of London. The Max Planck Society, the EU Horizon 2020 project Newcotiana (760331-2) and a grant from the European Research Council (ERC-ADG-2014; grant agreement 669982) to RB. KMOC, RMT and STH acknowledge support from the InnCoCells project funded by the European Union’s Horizon 2020 research and innovation programme under grant agreement 101000373. PSS, KAM, RF and SN are partially supported by a CRAFT award (COVID-19 Research Accelerator Funding Track) by the University of California Davis. KAM and SN were partially supported by NASA Space Technology Research (award number NNX17AJ31G) and by the Translational Research Institute through NASA (grant number NNX16AO69A); EMBRAPA (Brazilian Agricultural Corporation), INCT BioSyn (National Institute of Science and Technology in Synthetic Biology), CNPq, CAPES, Brazilian Ministry of Health, FAPDFnd Universidade Cat olica de Bras ılia (UCB), Bras ılia, Brazil; BBSRC Grant BB/L020955/1, the JIC Strategic Programme Grant ‘Molecules from Nature –Enhanced Research Capacity’ (BBS/E/ J/000PR9794), the John Innes Foundation and the Department of Health and Social Care using UK Aid funding managed by the BBSRC; and The Austrian Science Fund FWF (project W1224). TTW Veni Grant 16740 from the Netherlands Organization for Scientific Research. Research in the Daniell laboratory was supported by NIH grants R01 GM 63879, R01 107904, R01 HL 109442, R01 133191 and grants from Bayer, Novo Nordisk and Shire/Takeda. The National Heart Lung and Blood Institute, National Institutes of Health, Department of Health and Human Services, through the Science Moving TowArds Research Trans- lation and Therapy (SMARTT) programme contracts # HHSN268201600014C, HHSN268201600011C supported IND enabling regulatory, toxicology and pharmacokinetic studies. Any opinions, findings and conclusions or recommendations expressed in this material are those of the author (s) and do not necessarily reflect the views of the University of California, Davis, National Aeronautics and Space Administration (NASA) or the Translational Research Institute for Space Health (TRISH). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. Views expressed in this article are those of the authors and do not necessarily reflect those of the employing institutions or the UK Department of Health and Social Care
Repositori Obert UdL
Publicación Artículo científico (JournalArticle)

Cyanovirin-N binds to select SARS-CoV-2 spike oligosaccharides outside of the receptor binding domain and blocks infection by SARS-CoV-2

  • Muñoz-Basagoiti, Jordana
  • Monteiro, Fábio Luís Lima
  • Krumpe, Lauren R.H.
  • Armario-Nájera, Victoria
  • Shenoy, Shilpa R.
  • Perez-Zsolt, Daniel
  • Westgarth, Harrison James
  • Villorbina Noguera, Gemma
  • Bomfim, Larissa Maciel
  • Raïch-Regué, Dàlia
  • Nogueras Penabad, Lara
  • Henrich, Curtis J.
  • Gallemí, Marçal
  • Moreira, Filipe Romero Rebello
  • Torres Cabestany, Pascual
  • Wilson, Jennifer
  • D’arc, Mirela
  • Marfil, Silvia
  • Herlinger, Alice Laschuk
  • Pradenas, Edwards
  • Higa, Luiza Mendonça
  • Portero Otín, Manuel
  • Trinité, Benjamin
  • Twyman, Richard M.
  • Capell Capell, Teresa
  • Tanuri, Amilcar
  • Blanco, Julià
  • Izquierdo-Useros, Nuria
  • Rech, Elibio L.
  • Christou, Paul
  • O’Keefec, Barry R.
  • Higa, Higa,Luiza Mendonça
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped positive stranded RNA virus which has caused the recent deadly pandemic called COVID-19. The SARS-CoV-2 virion is coated with a heavily glycosylated Spike glycoprotein which is responsible for attachment and entry into target cells. One, as yet unexploited strategy for preventing SARS-CoV-2 infections, is the targeting of the glycans on Spike. Lectins are carbohydrate-binding proteins produced by plants, algae, and cyanobacteria. Some lectins can neutralize enveloped viruses displaying external glycoproteins, offering an alternative therapeutic approach for the prevention of infection with virulent β-coronaviruses, such as SARS-CoV-2. Here we show that the cyanobacterial lectin cyanovirin-N (CV-N) can selectively target SARS-CoV-2 Spike oligosaccharides and inhibit SARS-CoV-2 infection in vitro and in vivo. CV-N neutralizes Delta and Omicron variants in vitro better than earlier circulating viral variants. CV-N binds selectively to Spike with a Kd as low as 15 nM and a stoichiometry of 2 CV-N: 1 Spike but does not bind to the receptor binding domain (RBD). Further mapping of CV-N binding sites on Spike shows that select high-mannose oligosaccharides in the S1 domain of Spike are targeted by CV-N. CV-N also reduced viral loads in the nares and lungs in vivo to protect hamsters against a lethal viral challenge. In summary, we present an anti-coronavirus agent that works by an unexploited mechanism and prevents infection by a broad range of SARS-CoV-2 strains., Agricultural Biotechnology and Bioeconomy Unit (ABBU), Universitat de Lleida, Spain, EU Pharma-Factory grant agreement 77,4078 to P.C. Research in NI-U’s lab is supported by the Spanish Ministry of Science and Innovation (grant PID2020-117145RB-I00),EU HORIZON-HLTH-2021-CORONA-01 (grant 101046118) and by institutional funding of Grifols,Pharma Mar,HIPRA,Amassence,and Palobiofarma. E.L.R. is supported by Embrapa Genetic Resources and Biotechnology/National Institute of Science and Technology in Synthetic Biology, National Council for Scientific and Technological Development (465603/2014-9), Research Support Foundation of the Federal District (0193.001.262/2017), and Coordination for the Improvement of Higher Education Personnel. This research has been supported in part by the Intramural Research Program of the NIH, NCI, Center for Cancer Research and with federal funds from the NCI, NIH, under contract HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S.Government.All animal experiments were approved by
Repositori Obert UdL
Publicación Artículo científico (JournalArticle)

Physicochemical characterization of the recombinant lectin scytovirin and microbicidal activity of the SD1 domain produced in rice against HIV-1

  • Blanco Perera, Amaya
  • Shenoy, Shilpa R.
  • Sun, Yi
  • Marfil, Silvia
  • Muñoz‑Basagoiti, Jordana
  • Perez‑Zsolt, Daniel
  • Blanco, Julià
  • Izquierdo‑Useros, Nuria
  • Capell Capell, Teresa
  • Christou, Paul
Scytovirin (SVN) is an HIV-neutralizing lectin that features two structural domains (SD1 and SD2) that bind to HIV-1 envelope glycoproteins. We expressed SD1 in rice seeds as a potential large-scale production platform and confirmed that rice-derived SD1 binds the HIV-1 envelope glycoprotein gp120 in vitro. We analyzed the thermodynamic properties of SD1 compared to full-size SVN (produced in E. coli) by isothermal titration and differential scanning calorimetry to characterize the specific interactions between SVN/SD1 and gp120 as well as to high-mannose oligosaccharides. SVN bound with moderate affinity (K-d = 1.5 mu M) to recombinant gp120, with 2.5-fold weaker affinity to nonamannoside (K-d of 3.9 mu M), and with tenfold weaker affinity to tetramannoside (13.8 mu M). The melting temperature (T-m) of full-size SVN was 59.1 degrees C and the enthalpy of unfolding (Delta H-unf) was 16.4 kcal/mol, but the T-m fell when SVN bound to nonamannoside (56.5 degrees C) and twice as much energy was required for unfolding (Delta H-unf =33.5 kcal/mol). Interestingly, binding to tetramannoside destabilized the structure of SD1 (Delta T-m similar to 11.5 degrees C) and doubled the enthalpy of unfolding, suggesting a dimerization event. The similar melting phenomenon shared by SVN and SD1 in the presence of oligomannose confirmed their conserved oligosaccharide-binding mechanisms. SD1 expressed in transgenic rice was able to neutralize HIV-1 in vitro. SD1 expressed in rice, therefore, is suitable as a microbicide component., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This work was supported by Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR), Departament d'Empresa i Coneixement de la Generalitat de Catalunya (PANDEMIES 2020), MINECO, Spain (AGL2017-85377-R to T. Capell), Generalitat de Catalunya Grant 2017 SGR 828 to the Agricultural Biotechnology and Bioeconomy Unit (ABBU), CERCA Programme/Generalitat de Catalunya 2017 SGR 252 to IrsiCaixa, EU Pharma-Factory grant agreement 774078 to P. Christou and J. Blanco. A. Blanco-Perera was supported by a UdL fellowship. This research was supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government. This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under contract HHSN261201800001I.
Repositori Obert UdL
Publicación Artículo científico (JournalArticle)

Contributions of the international plant science community to the fight against infectious diseases in humans - part 1: epidemic and pandemic diseases, including HIV/AIDS and coronaviruses

  • Lobato, Maria
  • Huang, Xin
  • Alvarez, Derry
  • He, Wenshu
  • Baysal, Can
  • Zhu, Changfu
  • Armario-Nájera, Victoria
  • Blanco Perera, Amaya
  • Cerda, Pedro
  • Saba-Mayoral, Andrea
  • Sobrino-Mengual, Guillermo
  • Vargheese, Ashwin
  • Abranches, Rita
  • Abreu, Isabel Alexandra
  • Balamurugan, Shanmugaraj
  • Bock, Ralph
  • Buyel, Johannes F.
  • Cunha, Nicolau B. da
  • Daniell, Henry
  • Faller, Roland
  • Folgado, André
  • Gowtham, Iyappan
  • Häkkinen, Suvi
  • Kumar, Shashi
  • Sathish Kumar, Ramalingam
  • Lacorte, Cristiano
  • Lomonossoff, George P.
  • Luís, Ines M.
  • Ma, Julian K-C
  • McDonald, Karen A.
  • Murad, Andre
  • Nandi, Somen
  • O'Keef, Barry
  • Oksman-Caldentey, Kirsi-Marja
  • Parthiban, Subramanian
  • Paul, Mathew J.
  • Ponndorf, Daniel
  • Rech, Elibio
  • Rodrigues, Julio C. M.
  • Ruf, Stephanie
  • Schillberg, Stefan
  • Schwestka, Jennifer
  • Shah, Priya S.
  • Singh, Rahul
  • Stoger, Eva
  • Twyman, Richard M.
  • Varghese, Inchakalody P.
  • Vianna, Giovanni R.
  • Webster, Gina
  • Wilbers, Ruud H. P.
  • Capell Capell, Teresa
  • Christou, Paul
Infectious diseases, also known as transmissible or communicable diseases, are caused by pathogens or parasites that spread in communities by direct contact with infected individuals or contaminated materials, through droplets and aerosols, or via vectors such as insects. Such diseases cause 17% of all human deaths and their management and control places an immense burden on healthcare systems worldwide. Traditional approaches for the prevention and control of infectious diseases include vaccination programmes, hygiene measures and drugs that suppress the pathogen, treat the disease symptoms or attenuate aggressive reactions of the host immune system. The provision of vaccines and biologic drugs such as antibodies is hampered by the high cost and limited scalability of traditional manufacturing platforms based on microbial and animal cells, particularly in developing countries where infectious diseases are prevalent and poorly controlled. Molecular farming, which uses plants for protein expression, is a promising strategy to address the drawbacks of current manufacturing platforms. In this review article, we consider the potential of molecular farming to address healthcare demands for the most prevalent and important epidemic and pandemic diseases, focussing on recent outbreaks of high-mortality coronavirus infections and diseases that disproportionately affect the developing world., The authors would like to thank the Spanish Ministry of Economy, Industry and Competitiveness (project AGL2017-85377-R), the Spanish Ministry of Science, Innovation and Universities (projects RTI2018-097613-B-I00 and PGC2018-097655-B-I00), the EU Horizon 2020 project Pharma-Factory (774078) and the Gener- alitat de Catalunya (Grups Consolidats 2017-SGR828), Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR), Departa- ment d’Empresa i Coneixement de la Generalitat de Catalunya (PAND EMIES 2020). Project LISBOA-01-0145-FEDER-007660 (Microbiologia Molecular, Estrutural e Celular funded by FEDER funds through COMPETE2020 –Programa Operacional Compet- itividade e Internacionalizacß~ao (POCI) and by the FCT (Portugal) through the R&D Unit, UIDB/04551/2020 (GREEN-IT –Biore- sources for Sustainability). UKIERI and the Hotung Foundation for sustained support of the Bharathiar University / St. George’s Univ. of London collaboration and the Molecular Immunology Unit at St. George’s Univ of London. The Max Planck Society, the EU Horizon 2020 project Newcotiana, 760331-2) and a grant from the European Research Council (ERC-ADG-2014; grant agree- ment 669982) to RB. KMOC, RMT and STH acknowledge support from the InnCoCells project funded by the European Union’s Horizon 2020 research and innovation programme under grant agreement 101000373. PSS, KAM, RF, and SN are partially supported by a CRAFT award (COVID-19 Research Accelerator Funding Track) by the University of California Davis. KAM and SN were partially supported by NASA Space Technology Research (award number NNX17AJ31G) and by the Translational Research Institute through NASA (grant number NNX16AO69A). EMBRAPA (Brazilian Agricultural Corporation), INCT BioSyn (National Institute of Science and Technology in Synthetic Biology), CNPq, CAPES, Brazilian Ministry of Health, FAPDF and Universidade Cat olica de Bras ılia (UCB), Bras ılia, Brazil. BBSRC Grant BB/L020955/1, the JIC Strategic Programme Grant ‘Molecules from Nature –Enhanced Research Capacity’ (BBS/E/ J/000PR9794), the John Innes Foundation and the Department of Health and Social Care using UK Aid funding managed by the BBSRC. The Austrian Science Fund FWF (project W1224). TTW Veni Grant 16740 from the Netherlands Organization for Scientific Research. Research in the Daniell laboratory was supported by NIH grants R01 GM 63879, R01 107904, R01 HL 109442, R01 133191 and grants from Bayer, Novo Nordisk and Shire/Takeda. The National Heart Lung and Blood Institute, National Institutes of Health, Department of Healthand Human Services, through the Science Moving TowArds Research Trans- lation and Therapy (SMARTT) program contracts # HHSN268201600014C, HHSN268201600011C supported IND enabling regulatory, toxicology and pharmacokinetic studies. Any opinions, findings, and conclusions or recommendations expressed in this material are those of the author (s) and do not necessarily reflect the views of the University of California, Davis, National Aeronautics and Space Administration (NASA) or the Translational Research Institute for Space Health (TRISH). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. Views expressed in this article are those of the authors and do not necessarily reflect those of the employing institutions or the UK Department of Health and Social Care.
Repositori Obert UdL
Publicación Artículo científico (JournalArticle)

Iron and Zinc in the Embryo and Endosperm of Rice (Oryza sativa L.) Seeds in Contrasting 20-Deoxymugineic Acid/Nicotianamine Scenarios

  • Díaz-Benito, Pablo
  • Banakar, Raviraj
  • Rodríguez-Menéndez, Sara
  • Capell Capell, Teresa
  • Pereiro, Rosario
  • Christou, Paul
  • Abadía Bayona, Javier
  • Fernández, Beatriz
  • Álvarez-Fernández, Ana
Iron and Zn deficiencies are worldwide nutritional disorders that can be alleviated by increasing the metal concentration of rice (Oryza sativa L.) grains via bio-fortification approaches. The overproduction of the metal chelator nicotianamine (NA) is among the most effective ones, but it is still unclear whether this is due to the enrichment in NA itself and/or the concomitant enrichment in the NA derivative 20-deoxymugineic acid (DMA). The endosperm is the most commonly consumed portion of the rice grain and mediates the transfer of nutrients from vegetative tissues to the metal rich embryo. The impact of contrasting levels of DMA and NA on the metal distribution in the embryo and endosperm of rice seeds has been assessed using wild-type rice and six different transgenic lines overexpressing nicotianamine synthase (OsNAS1) and/or barley nicotianamine amino transferase (HvNAATb). These transgenic lines outlined three different DMA/NA scenarios: (i) in a first scenario, an enhanced NA level (via overexpression of OsNAS1) would not be fully depleted because of a limited capacity to use NA for DMA synthesis (lack of -or low- expression of HvNAATb), and results in consistent enrichments in NA, DMA, Fe and Zn in the endosperm and NA, DMA and Fe in the embryo; (ii) in a second scenario, an enhanced NA level (via overexpression of OsNAS1) would be depleted by an enhanced capacity to use NA for DMA synthesis (via expression of HvNAATb), and results in enrichments only for DMA and Fe, both in the endosperm and embryo, and (iii) in a third scenario, the lack of sufficient NA replenishment would limit DMA synthesis, in spite of the enhanced capacity to use NA for this purpose (via expression of HvNAATb), and results in decreases in NA, variable changes in DMA and moderate decreases in Fe in the embryo and endosperm. Also, quantitative LA-ICP-MS metal map images of the embryo structures show that the first and second scenarios altered local distributions of Fe, and to a lesser extent of Zn. The roles of DMA/NA levels in the transport of Fe and Zn within the embryo are thoroughly discussed., This work was supported by the grants of the Spanish Ministry of Science, Innovation and Universities (AGL2016-75226-R, BIO2014-54426-P and AGL2017-85377-R, all co-financed with FEDER), Aragón Government (Group A09_17R) and Generalitat de Catalunya (Grant 2017 SGR 828). PD-B was supported by a MINECO-FPI contract. RB was supported by a Ph.D. fellowship from the University of Lleida. SR-M was supported by a research contract from the Fundación Universidad de Oviedo (FUO-069-17). BF was supported by a MINECO research contract (RYC-2014-14985; “Ramón y Cajal Program”).
Repositori Obert UdL
Publicación Artículo científico (JournalArticle)

Unexpected synergistic HIV neutralization by a triple microbicide produced in rice endosperm

  • Vamvaka, Evangelia
  • Farré Martinez, Gemma
  • Molinos-Albert, Luis M.
  • Evans, Abbey
  • Canela Xandri, Anna
  • Twyman, Richard M.
  • Carrillo, Jorge
  • Ordóñez, Raziel Antonio
  • Shattock, Robin J.
  • O’Keef, Barry R.
  • Clotet, Bonaventura
  • Blanco, Julian
  • Khush, Gurdev S.
  • Christou, Paul
  • Capell Capell, Teresa
The transmission of HIV can be prevented by the application of neutralizing monoclonal antibodies and lectins. Traditional recombinant protein manufacturing platforms lack sufficient capacity and are too expensive for developing countries, which suffer the greatest disease burden. Plants offer an inexpensive and scalable alternative manufacturing platform that can produce multiple components in a single plant, which is important because multiple components are required to avoid the rapid emergence of HIV-1 strains resistant to single microbicides. Furthermore, crude extracts can be used directly for prophylaxis to avoid the massive costs of downstream processing and purification. We investigated whether rice could simultaneously produce three functional HIV-neutralizing proteins (the monoclonal antibody 2G12, and the lectins griffithsin and cyanovirin-N). Preliminary in vitro tests showed that the cocktail of three proteins bound to gp120 and achieved HIV-1 neutralization. Remarkably, when we mixed the components with crude extracts of wild-type rice endosperm, we observed enhanced binding to gp120 in vitro and synergistic neutralization when all three components were present. Extracts of transgenic plants expressing all three proteins also showed enhanced in vitro binding to gp120 and synergistic HIV-1 neutralization. Fractionation of the rice extracts suggested that the enhanced gp120 binding was dependent on rice proteins, primarily the globulin fraction. Therefore, the production of HIV-1 microbicides in rice may not only reduce costs compared to traditional platforms but may also provide functional benefits in terms of microbicidal potency., We thank Ms. Jennifer Wilson for technical assistance with live-virus anti-HIV assays. We received funding from Spanish Ministry of Science and Innovation Grant BIO2014-54426-P; Spanish Ministry of Economy, Industry and Competitiveness Grant AGL2017-85377-R; the European Fund for Economic and Regional Development; Generalitat de Catalunya Grant 2017 SGR 828 to the Agricultural Biotechnology and Bioeconomy Unit; and European Union Farma-Factory Grant Agreement 774078, H2020-BB-2016-2017/H2020-BB-2017-1. This project was funded in whole or in part with federal funds from the National Cancer Institute (NCI), NIH, under Contract HHSN26120080001E and was supported in part by the Intramural Research Program of the NIH, NCI, Center for Cancer Research, and Instituto de Salud Carlos III project PI14/01307. The EVA648 W61D and gp120 0607 IIIB were provided by the Medical Research Center Centralized Facility for AIDS reagents. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does the mention of trade names, commercial products, or organizations imply endorsement by the US government.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Contributions of the international plant science community to the fight against infectious diseases in humans - part 2: endemic and re-emerging diseases

  • He, Wenshu
  • Baysal, Can
  • Lobato, Maria
  • Huang, Xin
  • Alvarez, Derry
  • Zhu, Changfu
  • Armario-Nájera, Victoria
  • Blanco Perera, Amaya
  • Cerda, Pedro
  • Saba-Mayoral, Andrea
  • Sobrino-Mengual, Guillermo
  • Vargheese, Ashwin
  • Abranches, Rita
  • Abreu, Isabel Alexandra
  • Balamurugan, Shanmugaraj
  • Bock, Ralph
  • Buyel, Johannes F.
  • Cunha, Nicolau B. da
  • Daniell, Henry
  • Faller, Roland
  • Folgado, André
  • Gowtham, Iyappan
  • Häkkinen, Suvi
  • Kumar, Shashi
  • Sathish Kumar, Ramalingam
  • Lacorte, Cristiano
  • Lomonossoff, George P.
  • Luís, Ines M.
  • Ma, Julian K-C
  • McDonald, Karen A.
  • Murad, Andre
  • Nandi, Somen
  • O'Keef, Barry
  • Parthiban, Subramanian
  • Paul, Mathew J.
  • Ponndorf, Daniel
  • Rech, Elibio
  • Rodrigues, Julio C. M.
  • Ruf, Stephanie
  • Schillberg, Stefan
  • Schwestka, Jennifer
  • Shah, Priya S.
  • Singh, Rahul
  • Stoger, Eva
  • Twyman, Richard M.
  • Varghese, Inchakalody P.
  • Vianna, Giovanni R.
  • Webster, Gina
  • Wilbers, Ruud H. P.
  • Christou, Paul
  • Oksman-Caldentey, Kirsi-Marja
  • Capell Capell, Teresa
The fight against infectious diseases often focuses on epidemics and pandemics, which demand urgent resources and command attention from the health authorities and media. However, the vast majority of deaths caused by infectious diseases occur in endemic zones, particularly in developing countries, placing a disproportionate burden on underfunded health systems and often requiring international interventions. The provision of vaccines and other biologics is hampered not only by the high cost and limited scalability of traditional manufacturing platforms based on microbial and animal cells, but also by challenges caused by distribution and storage, particularly in regions without a complete cold chain. In this review article, we consider the potential of molecular farming to address the challenges of endemic and re-emerging diseases, focusing on edible plants for the development of oral drugs. Key recent developments in this field include successful clinical trials based on orally delivered dried leaves of Artemisia annua against malarial parasite strains resistant to artemisinin combination therapy, the ability to produce clinical-grade protein drugs in leaves to treat infectious diseases and the long-term storage of protein drugs in dried leaves at ambient temperatures. Recent FDA approval of the first orally delivered protein drug encapsulated in plant cells to treat peanut allergy has opened the door for the development of affordable oral drugs that can be manufactured and distributed in remote areas without cold storage infrastructure and that eliminate the need for expensive purification steps and sterile delivery by injection., The authors would like to thank the Spanish Ministry of Economy, Industry and Competitiveness (project AGL2017-85377-R), the Spanish Ministry of Science, Innovation and Universities (projects RTI2018-097613-B-I00 and PGC2018-097655-B-I00), the EU Horizon 2020 project Pharma-Factory (774078) and the Gener- alitat de Catalunya (Grups Consolidats2017-SGR828); Ag encia de Gesti o d’Ajuts Universitaris i de Recerca (AGAUR), Departament d’Empresa i Coneixement de la Generalitat de Catalunya (PAND EMIES 2020); Project LISBOA-01-0145-FEDER-007660 (Microbiologia Molecular, Estrutural e Celular funded by FEDER funds through COMPETE2020)—Programa Operacional Compet- itividade e Internacionalizacß~ao (POCI) and by the FCT (Portugal) through the R&D Unit, UIDB/04551/2020 (GREEN-IT—Biore- sources for Sustainability); UKIERI and the Hotung Foundation for sustained support of the Bharathiar University / St. George’s Univ. of London collaboration and the Molecular Immunology Unit at St. George’s Univ. of London. The Max Planck Society, the EU Horizon 2020 project Newcotiana (760331-2) and a grant from the European Research Council (ERC-ADG-2014; grant agreement 669982) to RB. KMOC, RMT and STH acknowledge support from the InnCoCells project funded by the European Union’s Horizon 2020 research and innovation programme under grant agreement 101000373. PSS, KAM, RF and SN are partially supported by a CRAFT award (COVID-19 Research Accelerator Funding Track) by the University of California Davis. KAM and SN were partially supported by NASA Space Technology Research (award number NNX17AJ31G) and by the Translational Research Institute through NASA (grant number NNX16AO69A); EMBRAPA (Brazilian Agricultural Corporation), INCT BioSyn (National Institute of Science and Technology in Synthetic Biology), CNPq, CAPES, Brazilian Ministry of Health, FAPDFnd Universidade Cat olica de Bras ılia (UCB), Bras ılia, Brazil; BBSRC Grant BB/L020955/1, the JIC Strategic Programme Grant ‘Molecules from Nature –Enhanced Research Capacity’ (BBS/E/ J/000PR9794), the John Innes Foundation and the Department of Health and Social Care using UK Aid funding managed by the BBSRC; and The Austrian Science Fund FWF (project W1224). TTW Veni Grant 16740 from the Netherlands Organization for Scientific Research. Research in the Daniell laboratory was supported by NIH grants R01 GM 63879, R01 107904, R01 HL 109442, R01 133191 and grants from Bayer, Novo Nordisk and Shire/Takeda. The National Heart Lung and Blood Institute, National Institutes of Health, Department of Health and Human Services, through the Science Moving TowArds Research Trans- lation and Therapy (SMARTT) programme contracts # HHSN268201600014C, HHSN268201600011C supported IND enabling regulatory, toxicology and pharmacokinetic studies. Any opinions, findings and conclusions or recommendations expressed in this material are those of the author (s) and do not necessarily reflect the views of the University of California, Davis, National Aeronautics and Space Administration (NASA) or the Translational Research Institute for Space Health (TRISH). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. Views expressed in this article are those of the authors and do not necessarily reflect those of the employing institutions or the UK Department of Health and Social Care
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Contributions of the international plant science community to the fight against infectious diseases in humans - part 1: epidemic and pandemic diseases, including HIV/AIDS and coronaviruses

  • Lobato, Maria
  • Huang, Xin
  • Alvarez, Derry
  • He, Wenshu
  • Baysal, Can
  • Zhu, Changfu
  • Armario-Nájera, Victoria
  • Blanco Perera, Amaya
  • Cerda, Pedro
  • Saba-Mayoral, Andrea
  • Sobrino-Mengual, Guillermo
  • Vargheese, Ashwin
  • Abranches, Rita
  • Abreu, Isabel Alexandra
  • Balamurugan, Shanmugaraj
  • Bock, Ralph
  • Buyel, Johannes F.
  • Cunha, Nicolau B. da
  • Daniell, Henry
  • Faller, Roland
  • Folgado, André
  • Gowtham, Iyappan
  • Häkkinen, Suvi
  • Kumar, Shashi
  • Sathish Kumar, Ramalingam
  • Lacorte, Cristiano
  • Lomonossoff, George P.
  • Luís, Ines M.
  • Ma, Julian K-C
  • McDonald, Karen A.
  • Murad, Andre
  • Nandi, Somen
  • O'Keef, Barry
  • Oksman-Caldentey, Kirsi-Marja
  • Parthiban, Subramanian
  • Paul, Mathew J.
  • Ponndorf, Daniel
  • Rech, Elibio
  • Rodrigues, Julio C. M.
  • Ruf, Stephanie
  • Schillberg, Stefan
  • Schwestka, Jennifer
  • Shah, Priya S.
  • Singh, Rahul
  • Stoger, Eva
  • Twyman, Richard M.
  • Varghese, Inchakalody P.
  • Vianna, Giovanni R.
  • Webster, Gina
  • Wilbers, Ruud H. P.
  • Capell Capell, Teresa
  • Christou, Paul
Infectious diseases, also known as transmissible or communicable diseases, are caused by pathogens or parasites that spread in communities by direct contact with infected individuals or contaminated materials, through droplets and aerosols, or via vectors such as insects. Such diseases cause 17% of all human deaths and their management and control places an immense burden on healthcare systems worldwide. Traditional approaches for the prevention and control of infectious diseases include vaccination programmes, hygiene measures and drugs that suppress the pathogen, treat the disease symptoms or attenuate aggressive reactions of the host immune system. The provision of vaccines and biologic drugs such as antibodies is hampered by the high cost and limited scalability of traditional manufacturing platforms based on microbial and animal cells, particularly in developing countries where infectious diseases are prevalent and poorly controlled. Molecular farming, which uses plants for protein expression, is a promising strategy to address the drawbacks of current manufacturing platforms. In this review article, we consider the potential of molecular farming to address healthcare demands for the most prevalent and important epidemic and pandemic diseases, focussing on recent outbreaks of high-mortality coronavirus infections and diseases that disproportionately affect the developing world., The authors would like to thank the Spanish Ministry of Economy, Industry and Competitiveness (project AGL2017-85377-R), the Spanish Ministry of Science, Innovation and Universities (projects RTI2018-097613-B-I00 and PGC2018-097655-B-I00), the EU Horizon 2020 project Pharma-Factory (774078) and the Gener- alitat de Catalunya (Grups Consolidats 2017-SGR828), Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR), Departa- ment d’Empresa i Coneixement de la Generalitat de Catalunya (PAND EMIES 2020). Project LISBOA-01-0145-FEDER-007660 (Microbiologia Molecular, Estrutural e Celular funded by FEDER funds through COMPETE2020 –Programa Operacional Compet- itividade e Internacionalizacß~ao (POCI) and by the FCT (Portugal) through the R&D Unit, UIDB/04551/2020 (GREEN-IT –Biore- sources for Sustainability). UKIERI and the Hotung Foundation for sustained support of the Bharathiar University / St. George’s Univ. of London collaboration and the Molecular Immunology Unit at St. George’s Univ of London. The Max Planck Society, the EU Horizon 2020 project Newcotiana, 760331-2) and a grant from the European Research Council (ERC-ADG-2014; grant agree- ment 669982) to RB. KMOC, RMT and STH acknowledge support from the InnCoCells project funded by the European Union’s Horizon 2020 research and innovation programme under grant agreement 101000373. PSS, KAM, RF, and SN are partially supported by a CRAFT award (COVID-19 Research Accelerator Funding Track) by the University of California Davis. KAM and SN were partially supported by NASA Space Technology Research (award number NNX17AJ31G) and by the Translational Research Institute through NASA (grant number NNX16AO69A). EMBRAPA (Brazilian Agricultural Corporation), INCT BioSyn (National Institute of Science and Technology in Synthetic Biology), CNPq, CAPES, Brazilian Ministry of Health, FAPDF and Universidade Cat olica de Bras ılia (UCB), Bras ılia, Brazil. BBSRC Grant BB/L020955/1, the JIC Strategic Programme Grant ‘Molecules from Nature –Enhanced Research Capacity’ (BBS/E/ J/000PR9794), the John Innes Foundation and the Department of Health and Social Care using UK Aid funding managed by the BBSRC. The Austrian Science Fund FWF (project W1224). TTW Veni Grant 16740 from the Netherlands Organization for Scientific Research. Research in the Daniell laboratory was supported by NIH grants R01 GM 63879, R01 107904, R01 HL 109442, R01 133191 and grants from Bayer, Novo Nordisk and Shire/Takeda. The National Heart Lung and Blood Institute, National Institutes of Health, Department of Healthand Human Services, through the Science Moving TowArds Research Trans- lation and Therapy (SMARTT) program contracts # HHSN268201600014C, HHSN268201600011C supported IND enabling regulatory, toxicology and pharmacokinetic studies. Any opinions, findings, and conclusions or recommendations expressed in this material are those of the author (s) and do not necessarily reflect the views of the University of California, Davis, National Aeronautics and Space Administration (NASA) or the Translational Research Institute for Space Health (TRISH). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. Views expressed in this article are those of the authors and do not necessarily reflect those of the employing institutions or the UK Department of Health and Social Care.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Iron and Zinc in the Embryo and Endosperm of Rice (Oryza sativa L.) Seeds in Contrasting 20-Deoxymugineic Acid/Nicotianamine Scenarios

  • Díaz-Benito, Pablo
  • Banakar, Raviraj
  • Rodríguez-Menéndez, Sara
  • Capell Capell, Teresa
  • Pereiro, Rosario
  • Christou, Paul
  • Abadía Bayona, Javier
  • Fernández, Beatriz
  • Álvarez-Fernández, Ana
Iron and Zn deficiencies are worldwide nutritional disorders that can be alleviated by increasing the metal concentration of rice (Oryza sativa L.) grains via bio-fortification approaches. The overproduction of the metal chelator nicotianamine (NA) is among the most effective ones, but it is still unclear whether this is due to the enrichment in NA itself and/or the concomitant enrichment in the NA derivative 20-deoxymugineic acid (DMA). The endosperm is the most commonly consumed portion of the rice grain and mediates the transfer of nutrients from vegetative tissues to the metal rich embryo. The impact of contrasting levels of DMA and NA on the metal distribution in the embryo and endosperm of rice seeds has been assessed using wild-type rice and six different transgenic lines overexpressing nicotianamine synthase (OsNAS1) and/or barley nicotianamine amino transferase (HvNAATb). These transgenic lines outlined three different DMA/NA scenarios: (i) in a first scenario, an enhanced NA level (via overexpression of OsNAS1) would not be fully depleted because of a limited capacity to use NA for DMA synthesis (lack of -or low- expression of HvNAATb), and results in consistent enrichments in NA, DMA, Fe and Zn in the endosperm and NA, DMA and Fe in the embryo; (ii) in a second scenario, an enhanced NA level (via overexpression of OsNAS1) would be depleted by an enhanced capacity to use NA for DMA synthesis (via expression of HvNAATb), and results in enrichments only for DMA and Fe, both in the endosperm and embryo, and (iii) in a third scenario, the lack of sufficient NA replenishment would limit DMA synthesis, in spite of the enhanced capacity to use NA for this purpose (via expression of HvNAATb), and results in decreases in NA, variable changes in DMA and moderate decreases in Fe in the embryo and endosperm. Also, quantitative LA-ICP-MS metal map images of the embryo structures show that the first and second scenarios altered local distributions of Fe, and to a lesser extent of Zn. The roles of DMA/NA levels in the transport of Fe and Zn within the embryo are thoroughly discussed., This work was supported by the grants of the Spanish Ministry of Science, Innovation and Universities (AGL2016-75226-R, BIO2014-54426-P and AGL2017-85377-R, all co-financed with FEDER), Aragón Government (Group A09_17R) and Generalitat de Catalunya (Grant 2017 SGR 828). PD-B was supported by a MINECO-FPI contract. RB was supported by a Ph.D. fellowship from the University of Lleida. SR-M was supported by a research contract from the Fundación Universidad de Oviedo (FUO-069-17). BF was supported by a MINECO research contract (RYC-2014-14985; “Ramón y Cajal Program”).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Cyanovirin-N binds to select SARS-CoV-2 spike oligosaccharides outside of the receptor binding domain and blocks infection by SARS-CoV-2

  • Muñoz-Basagoiti, Jordana
  • Monteiro, Fábio Luís Lima
  • Krumpe, Lauren R.H.
  • Armario-Nájera, Victoria
  • Shenoy, Shilpa R.
  • Perez-Zsolt, Daniel
  • Westgarth, Harrison James
  • Villorbina Noguera, Gemma
  • Bomfim, Larissa Maciel
  • Raïch-Regué, Dàlia
  • Nogueras Penabad, Lara
  • Henrich, Curtis J.
  • Gallemí, Marçal
  • Moreira, Filipe Romero Rebello
  • Torres Cabestany, Pascual
  • Wilson, Jennifer
  • D’arc, Mirela
  • Marfil, Silvia
  • Herlinger, Alice Laschuk
  • Pradenas, Edwards
  • Higa, Luiza Mendonça
  • Portero Otín, Manuel
  • Trinité, Benjamin
  • Twyman, Richard M.
  • Capell Capell, Teresa
  • Tanuri, Amilcar
  • Blanco, Julià
  • Izquierdo-Useros, Nuria
  • Rech, Elibio L.
  • Christou, Paul
  • O’Keefec, Barry R.
  • Higa, Higa,Luiza Mendonça
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped positive stranded RNA virus which has caused the recent deadly pandemic called COVID-19. The SARS-CoV-2 virion is coated with a heavily glycosylated Spike glycoprotein which is responsible for attachment and entry into target cells. One, as yet unexploited strategy for preventing SARS-CoV-2 infections, is the targeting of the glycans on Spike. Lectins are carbohydrate-binding proteins produced by plants, algae, and cyanobacteria. Some lectins can neutralize enveloped viruses displaying external glycoproteins, offering an alternative therapeutic approach for the prevention of infection with virulent β-coronaviruses, such as SARS-CoV-2. Here we show that the cyanobacterial lectin cyanovirin-N (CV-N) can selectively target SARS-CoV-2 Spike oligosaccharides and inhibit SARS-CoV-2 infection in vitro and in vivo. CV-N neutralizes Delta and Omicron variants in vitro better than earlier circulating viral variants. CV-N binds selectively to Spike with a Kd as low as 15 nM and a stoichiometry of 2 CV-N: 1 Spike but does not bind to the receptor binding domain (RBD). Further mapping of CV-N binding sites on Spike shows that select high-mannose oligosaccharides in the S1 domain of Spike are targeted by CV-N. CV-N also reduced viral loads in the nares and lungs in vivo to protect hamsters against a lethal viral challenge. In summary, we present an anti-coronavirus agent that works by an unexploited mechanism and prevents infection by a broad range of SARS-CoV-2 strains., Agricultural Biotechnology and Bioeconomy Unit (ABBU), Universitat de Lleida, Spain, EU Pharma-Factory grant agreement 77,4078 to P.C. Research in NI-U’s lab is supported by the Spanish Ministry of Science and Innovation (grant PID2020-117145RB-I00),EU HORIZON-HLTH-2021-CORONA-01 (grant 101046118) and by institutional funding of Grifols,Pharma Mar,HIPRA,Amassence,and Palobiofarma. E.L.R. is supported by Embrapa Genetic Resources and Biotechnology/National Institute of Science and Technology in Synthetic Biology, National Council for Scientific and Technological Development (465603/2014-9), Research Support Foundation of the Federal District (0193.001.262/2017), and Coordination for the Improvement of Higher Education Personnel. This research has been supported in part by the Intramural Research Program of the NIH, NCI, Center for Cancer Research and with federal funds from the NCI, NIH, under contract HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S.Government.All animal experiments were approved by
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Inactivation of rice starch branching enzyme IIb triggers broad and unexpected changes in metabolism by transcriptional reprogramming

  • Baysal, Can
  • He, Wenshu
  • Drapal, Margit
  • Villorbina Noguera, Gemma
  • Medina Piles, Vicente
  • Capell Capell, Teresa
  • Khush, Gurdev S.
  • Zhu, Changfu
  • Fraser, Paul
  • Christou, Paul
Starch properties can be modified by mutating genes responsible for the synthesis of amylose and amylopectin in the endosperm. However, little is known about the effects of such targeted modifications on the overall starch biosynthesis pathway and broader metabolism. Here we investigated the effects of mutating the OsSBEIIb gene encoding starch branching enzyme IIb, which is required for amylopectin synthesis in the endosperm. As anticipated, homozygous mutant plants, in which OsSBEIIb was completely inactivated by abolishing the catalytic center and C-terminal regulatory domain, produced opaque seeds with depleted starch reserves. Amylose content in the mutant increased from 19.6 to 27.4% and resistant starch (RS) content increased from 0.2 to 17.2%. Many genes encoding isoforms of AGPase, soluble starch synthase, and other starch branching enzymes were up-regulated, either in their native tissues or in an ectopic manner, whereas genes encoding granule-bound starch synthase, debranching enzymes, pullulanase, and starch phosphorylases were largely down-regulated. There was a general increase in the accumulation of sugars, fatty acids, amino acids, and phytosterols in the mutant endosperm, suggesting that intermediates in the starch biosynthesis pathway increased flux through spillover pathways causing a profound impact on the accumulation of multiple primary and secondary metabolites. Our results provide insights into the broader implications of perturbing starch metabolism in rice endosperm and its impact on the whole plant, which will make it easier to predict the effect of metabolic engineering in cereals for nutritional improvement or the production of valuable metabolites., We would like to acknowledge funding from Ministry of Economy and Competitiveness, Spain (RTI2018-097613-BI00 to C.Z., PGC2018-097655-B-I00 to P.C., and AGL2017-85377-R to T.C.); Generalitat de Catalunya Grant 2017 SGR 828 to the Agricultural Biotechnology and Bioeconomy Unit; and the European Union Framework Program DISCO (from discovery to final products: a next-generation pipeline for the sustainable generation of high-value plant products; Project 613513) to P.D.F.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Unexpected synergistic HIV neutralization by a triple microbicide produced in rice endosperm

  • Vamvaka, Evangelia
  • Farré Martinez, Gemma
  • Molinos-Albert, Luis M.
  • Evans, Abbey
  • Canela Xandri, Anna
  • Twyman, Richard M.
  • Carrillo, Jorge
  • Ordóñez, Raziel Antonio
  • Shattock, Robin J.
  • O’Keef, Barry R.
  • Clotet, Bonaventura
  • Blanco, Julian
  • Khush, Gurdev S.
  • Christou, Paul
  • Capell Capell, Teresa
The transmission of HIV can be prevented by the application of neutralizing monoclonal antibodies and lectins. Traditional recombinant protein manufacturing platforms lack sufficient capacity and are too expensive for developing countries, which suffer the greatest disease burden. Plants offer an inexpensive and scalable alternative manufacturing platform that can produce multiple components in a single plant, which is important because multiple components are required to avoid the rapid emergence of HIV-1 strains resistant to single microbicides. Furthermore, crude extracts can be used directly for prophylaxis to avoid the massive costs of downstream processing and purification. We investigated whether rice could simultaneously produce three functional HIV-neutralizing proteins (the monoclonal antibody 2G12, and the lectins griffithsin and cyanovirin-N). Preliminary in vitro tests showed that the cocktail of three proteins bound to gp120 and achieved HIV-1 neutralization. Remarkably, when we mixed the components with crude extracts of wild-type rice endosperm, we observed enhanced binding to gp120 in vitro and synergistic neutralization when all three components were present. Extracts of transgenic plants expressing all three proteins also showed enhanced in vitro binding to gp120 and synergistic HIV-1 neutralization. Fractionation of the rice extracts suggested that the enhanced gp120 binding was dependent on rice proteins, primarily the globulin fraction. Therefore, the production of HIV-1 microbicides in rice may not only reduce costs compared to traditional platforms but may also provide functional benefits in terms of microbicidal potency., We thank Ms. Jennifer Wilson for technical assistance with live-virus anti-HIV assays. We received funding from Spanish Ministry of Science and Innovation Grant BIO2014-54426-P; Spanish Ministry of Economy, Industry and Competitiveness Grant AGL2017-85377-R; the European Fund for Economic and Regional Development; Generalitat de Catalunya Grant 2017 SGR 828 to the Agricultural Biotechnology and Bioeconomy Unit; and European Union Farma-Factory Grant Agreement 774078, H2020-BB-2016-2017/H2020-BB-2017-1. This project was funded in whole or in part with federal funds from the National Cancer Institute (NCI), NIH, under Contract HHSN26120080001E and was supported in part by the Intramural Research Program of the NIH, NCI, Center for Cancer Research, and Instituto de Salud Carlos III project PI14/01307. The EVA648 W61D and gp120 0607 IIIB were provided by the Medical Research Center Centralized Facility for AIDS reagents. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does the mention of trade names, commercial products, or organizations imply endorsement by the US government.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Physicochemical characterization of the recombinant lectin scytovirin and microbicidal activity of the SD1 domain produced in rice against HIV-1

  • Blanco Perera, Amaya
  • Shenoy, Shilpa R.
  • Sun, Yi
  • Marfil, Silvia
  • Muñoz‑Basagoiti, Jordana
  • Perez‑Zsolt, Daniel
  • Blanco, Julià
  • Izquierdo‑Useros, Nuria
  • Capell Capell, Teresa
  • Christou, Paul
Scytovirin (SVN) is an HIV-neutralizing lectin that features two structural domains (SD1 and SD2) that bind to HIV-1 envelope glycoproteins. We expressed SD1 in rice seeds as a potential large-scale production platform and confirmed that rice-derived SD1 binds the HIV-1 envelope glycoprotein gp120 in vitro. We analyzed the thermodynamic properties of SD1 compared to full-size SVN (produced in E. coli) by isothermal titration and differential scanning calorimetry to characterize the specific interactions between SVN/SD1 and gp120 as well as to high-mannose oligosaccharides. SVN bound with moderate affinity (K-d = 1.5 mu M) to recombinant gp120, with 2.5-fold weaker affinity to nonamannoside (K-d of 3.9 mu M), and with tenfold weaker affinity to tetramannoside (13.8 mu M). The melting temperature (T-m) of full-size SVN was 59.1 degrees C and the enthalpy of unfolding (Delta H-unf) was 16.4 kcal/mol, but the T-m fell when SVN bound to nonamannoside (56.5 degrees C) and twice as much energy was required for unfolding (Delta H-unf =33.5 kcal/mol). Interestingly, binding to tetramannoside destabilized the structure of SD1 (Delta T-m similar to 11.5 degrees C) and doubled the enthalpy of unfolding, suggesting a dimerization event. The similar melting phenomenon shared by SVN and SD1 in the presence of oligomannose confirmed their conserved oligosaccharide-binding mechanisms. SD1 expressed in transgenic rice was able to neutralize HIV-1 in vitro. SD1 expressed in rice, therefore, is suitable as a microbicide component., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This work was supported by Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR), Departament d'Empresa i Coneixement de la Generalitat de Catalunya (PANDEMIES 2020), MINECO, Spain (AGL2017-85377-R to T. Capell), Generalitat de Catalunya Grant 2017 SGR 828 to the Agricultural Biotechnology and Bioeconomy Unit (ABBU), CERCA Programme/Generalitat de Catalunya 2017 SGR 252 to IrsiCaixa, EU Pharma-Factory grant agreement 774078 to P. Christou and J. Blanco. A. Blanco-Perera was supported by a UdL fellowship. This research was supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government. This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under contract HHSN261201800001I.